{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:00:19Z","timestamp":1791651619997,"version":"4.3.4"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jaad.2022.06.1171","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T01:38:53Z","timestamp":1656293933000},"page":"800-806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING\u00a03 trial"],"prefix":"10.1016","volume":"87","author":[{"given":"Bruce","family":"Strober","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Stein Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bissonnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Kircik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen K.","family":"Tyring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Piscitelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip M.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Rubenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2022.06.1171_bib1","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaad.2020.10.085","article-title":"Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent","volume":"84","author":"Bissonnette","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2022.06.1171_bib2","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jaad.2002.12.002","article-title":"Combination therapy to treat moderate to severe psoriasis","volume":"50","author":"Lebwohl","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2022.06.1171_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40257-012-0003-7","article-title":"Combination therapy in psoriasis: an evidence-based review","volume":"14","author":"Gustafson","year":"2013","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2022.06.1171_bib4","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures","volume":"84","author":"Elmets","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2022.06.1171_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2022.100116","article-title":"The relapse of psoriasis: what's the veil of mystery?","volume":"2","author":"Tian","year":"2022","journal-title":"JID Innov"},{"key":"10.1016\/j.jaad.2022.06.1171_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40257-021-00641-4","article-title":"Tapinarof cream 1% for extensive plaque psoriasis: a maximal use trial on safety, tolerability, and pharmacokinetics","volume":"23","author":"Jett","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2022.06.1171_bib7","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2103629","article-title":"Phase 3 trials of tapinarof cream for plaque psoriasis","volume":"385","author":"Lebwohl","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2022.06.1171_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2021.06.310","article-title":"Tapinarof cream 1% once daily for plaque psoriasis: patient-reported outcomes from two pivotal phase 3 trials.","author":"Bissonnette","year":"2021","journal-title":"Presented at the American Academy of Dermatology VMX (virtual)"},{"key":"10.1016\/j.jaad.2022.06.1171_bib9","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2018.10.037","article-title":"Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis","volume":"80","author":"Robbins","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2022.06.1171_bib10","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/j.1468-3083.2011.04332.x","article-title":"Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial","volume":"26","author":"Bissonnette","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2022.06.1171_bib12","doi-asserted-by":"crossref","first-page":"ii83","DOI":"10.1136\/ard.2004.030791","article-title":"Psoriasis treatment: traditional therapy","volume":"64","author":"Lebwohl","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2022.06.1171_bib13","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.12788\/j.sder.2016.022","article-title":"Why biologic therapies sometimes lose efficacy","volume":"35","author":"Strober","year":"2016","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jaad.2022.06.1171_bib14","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.jid.2017.05.004","article-title":"Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans","volume":"137","author":"Smith","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2022.06.1171_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023522","article-title":"Activation of aryl hydrocarbon receptor (AhR) leads to reciprocal epigenetic regulation of FoxP3 and IL-17 expression and amelioration of experimental colitis","volume":"6","author":"Singh","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jaad.2022.06.1171_bib16","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1073\/pnas.1322292111","article-title":"Persistence of skin-resident memory T cells within an epidermal niche","volume":"111","author":"Zaid","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaad.2022.06.1171_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2022.05.1011","article-title":"Tapinarof inhibits the formation, cytokine production, and persistence of resident memory T cells in vitro","author":"Mooney","year":"2022","journal-title":"Society For Investigative Dermatology"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222022198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222022198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:05:15Z","timestamp":1759273515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962222022198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0190962222022198"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2022.06.1171","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING\u00a03 trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2022.06.1171","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}